Medicinova (MNOV) Other Non-Current Liabilities (2018 - 2025)
Medicinova (MNOV) posted quarterly Other Non-Current Liabilities of $17129.0 for Q4 2025, down 91.9% year-over-year from $211460.0 in Q4 2024, and down 76.98% quarter-over-quarter from $74399.0 in Q3 2025.
Medicinova (MNOV) Other Non-Current Liabilities (2018 - 2025) Analysis & Trends
Medicinova (MNOV) has reported Other Non-Current Liabilities for 8 consecutive years, with $17129.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 91.9% year-over-year to $17129.0; the TTM figure through Dec 2025 stood at $17129.0 (down 91.9% YoY), while the FY2025 annual figure was $17129.0, down 91.9% from the prior year.
- Other Non-Current Liabilities slipped to $17129.0 in Q4 2025 per MNOV's latest filing, from $74399.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $737716.0 in Q3 2021 and bottomed at $2211.0 in Q1 2021.
- Historically, Other Non-Current Liabilities has averaged $359947.2 across 5 years, with a median of $380922.5 in 2023.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities tumbled 98.27% — and 2022, when it surged 28523.65%.
- Medicinova's Other Non-Current Liabilities stood at $694674.0 in 2021, then fell by 24.62% to $523619.0 in 2022, then retreated by 21.57% to $410660.0 in 2023, then sank by 48.51% to $211460.0 in 2024, then sank by 91.9% to $17129.0 in 2025.
- Business Quant data shows MNOV's Other Non-Current Liabilities at $17129.0 in Q4 2025, $74399.0 in Q3 2025, and $117038.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17,129.00 |
| Sep 30, 2025 | 74,399.00 |
| Jun 30, 2025 | 117,038.00 |
| Mar 31, 2025 | 165,198.00 |
| Dec 31, 2024 | 211,460.00 |
| Sep 30, 2024 | 255,150.00 |
| Jun 30, 2024 | 302,483.00 |
| Mar 31, 2024 | 351,185.00 |
| Dec 31, 2023 | 410,660.00 |
| Sep 30, 2023 | 463,838.00 |
| Jun 30, 2023 | 519,685.00 |
| Mar 31, 2023 | 489,379.00 |
| Dec 31, 2022 | 523,619.00 |
| Sep 30, 2022 | 555,840.00 |
| Jun 30, 2022 | 587,404.00 |
| Mar 31, 2022 | 632,869.00 |
| Dec 31, 2021 | 694,674.00 |
| Sep 30, 2021 | 737,716.00 |
| Jun 30, 2021 | 87,007.00 |
| Mar 31, 2021 | 2,211.00 |